Instrumento Inactivo

Otros idiomas Antisense Therapeutics Limited Other OTC

Acciones

ATHJF

AU000000ANP4

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%	29/05
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels	09/10/23
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23
Antisense Therapeutics Appoints CEO/Managing Director	07/08/23
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023	07/08/23
Antisense Therapeutics Limited Announces Management Changes	07/08/23
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%	20/07/23
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	27/06/23
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%	08/06/23
Antisense Therapeutics Appoints CEO/Managing Director	08/05/23
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023	08/05/23
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director	08/05/23
Antisense Therapeutics Begins Dosing in Toxicology Study for Muscular Dystrophy Treatment	14/03/23
Antisense Therapeutics Limited Announces the Commencement of Dosing in the Nine-Month Chronic Monkey Toxicology Study of ATL1102	13/03/23
Antisense Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23
Antisense Therapeutics Secures Turkish Clearance for Phase 2 Muscular Dystrophy Trial	14/02/23
Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency	13/02/23
Antisense Therapeutics Starts Muscular Dystrophy Animal Study	13/02/23
Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency	12/02/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Antisense Therapeutics Limited Other OTC

Acciones

ATHJF

AU000000ANP4

Otros idiomas

Filtros